Original Research Article

Synergistic effect of a combination of granulocyte macrophage colony-stimulating factor and thymosin α1 on Lewis lung cancer transplanted tumor in mice

Haiyan Lan1*, Yanrong Hao1, Yanru Lv1, Guangyu Li2, Yuncong Mo3, Cheng Zheng2, Yuanfa Li2

1Department of Oncological Internal Medicine, People’s Hospital of Guangxi Zhuang Autonomous Region, 2Department of Andrology, 3Department of Nuclear Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China

*For correspondence: Email: d157ox@163.com

Sent for review: 22 January 2019
Revised accepted: 26 January 2020

Abstract

Purpose: To study the synergistic effect of a combination of granulocyte-macrophage colony-stimulating factor and thymosin-α1 on the treatment of Lewis lung cancer transplanted tumor.

Methods: C57BL/6 mice were used. A mouse model of Lewis lung cancer was established using Lewis lung cancer cell lines. The mice were randomly divided into blank control group, polyene taxol (DTX) group, DTX thymosin α1 (Tα-1) group, and DTX granulocyte-macrophage colony-stimulating factor (GM-CSF) group, with 8 mice per group. The degree of tumor inhibition, thymus mass, thymus index, spleen mass, spleen index, IL-6, TNF-1, IFN-1, CD4+, CD8+ T cells and the ratio of CD4+/CD8+ were determined by ELISA and flow cytometry.

Results: Body mass, thymus mass, thymus index, spleen mass, spleen index, IL-6, TNF-1, IFN-1, CD4+, CD8+ T cells and the ratio of CD4+/CD8+ in DTX + Tα-1 group, DTX + GM-CSF group and DTX + Tα-1 + GM-CSF group were significantly elevated (p < 0.05), relative to the corresponding levels in DTX mice (p < 0.05). Body mass, degree of tumor inhibition, thymus mass, thymus index, spleen mass, spleen index, IL-6, TNF-1, IFN-1, CD4, CD8 T cells and CD4+/CD8+ ratio in DTX + Tα-1 + GM-CSF mice were significantly elevated, relative to the DTX + Tα-1 and DTX + GM-CSF groups (p < 0.05). The state of the tumor was significantly improved in the DTX + Tα-1 and DTX + GM-CSF mice.

Conclusion: A combination treatment of GM-CSF, Tα-1 and DEX effectively enhances the resistance of mice and suppresses chemotherapy-induced decrease in body weight. This finding may be of clinical significance.

Keywords: Granulocyte macrophage, Colony-stimulating factor, Thymosin, Docetaxel, Lewis lung cancer, Transplanted tumor

INTRODUCTION

Over the years, cases of lung cancer have become accentuated, making it the malignant tumor with the highest incidence [1]. Available data show that about 10,000 people in China are diagnosed with cancer every day, among which lung carcinoma patients and lung cancer-related
deaths account for the largest proportion [2]. The cause of pulmonary cancer is not yet elucidated. However, studies have shown that lung cancer cases are markedly higher in habitual smokers than in the non-smoking individuals, and the younger the smoking age, the higher the prevalence of pulmonary cancer [3]. Moreover, the incidence of lung cancer in the urban population is markedly higher than that in rural dwellers, probably due to environmental pollution [3].

The clinical symptoms of early lung cancer are mild and often ignored, and most patients are diagnosed at the middle and late stages of the disease when they cannot benefit from operation [4]. Therefore, it is necessary to develop an effective and reliable chemotherapy to enhance clinical treatment for lung cancer. The treatment of lung cancer uses platinum-based chemotherapy, but the toxicity and side effects of chemotherapy limit its clinical application. The currently-used used drugs belong to the third-generation chemotherapy medicines, an example of which is polyene taxol [5].

Docetaxel (DTX), which is extracted from the Chinese yew, has unique anti-cancer properties, and is used in clinical practice for treatment of lung cancer. However, serious adverse reactions and drug resistance have resulted in low levels of clinical effect [6]. The GM-CSF enhances immunity and promotes the release of pro-inflammatory factors. In addition, its receptor maintains normal neutrophil counts [7]. Studies have shown that combination of GM-CSF and chemotherapy significantly inhibits tumor growth, reduces the incidence of toxicity and side effects, and enhances the immunity of the patient [8].

Thymosin (Tα1) promotes the maturation of CD8+ T cells, directly kills target cells, and enhances immune response. Clinical investigations have revealed that Tα1 inhibits cancer proliferation and promotes apoptosis [9]. In this study, combination of Tα1 and GM-CSF was used to treat a mouse model of Lewis lung cancer, with the aim of determining their synergistic effects.

EXPERIMENTAL

Animals

Forty C57BL/6 mice were obtained from Guangdong Medical Experimental Animal Center. The mice were 4 - 5 weeks old, with a mean body mass of 21 ± 3 g. Mouse Lewis lung cancer cell line was obtained from Shanghai Yaji Biotechnology Co. Ltd. This research was approved by the Animal Ethical Committee of Department of Oncological Internal Medicine, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning City, Guangxi Province, China (approval no. 201834045), and was carried out in line with the directives of "Principles of Laboratory Animal Care" (NIH, 1985) [10].

Reagents and instruments

The drugs/reagents and instruments used, and their sources (in brackets) were: docetaxel (Lini Azeroth Biotechnology Co. Ltd), thymosin-α1 (Shanghai Kangjiang Biotechnology Co. Ltd), GM-CSF (Nanjing Peptide Industry Biotechnology Co. Ltd), DMEM (Beijing Taizerda Science and Technology Co. Ltd), fetal bovine serum (Shenzhen Kangxi Biotech Co. Ltd), PBS buffer solution (Suzhou Heritage Biotech Co. Ltd.), 0.9 % sodium chloride injection (Jiangxi Jiangblue Pure Biological Reagent Co. Ltd), tetramethylbenzidine (Sigma Co. Ltd), ether (Biotech Co. Ltd.), anhydrous ethyl ether (Beijing Dinghongsheng Biotechnology Co. Ltd), Enzyme-linked Immunoassay Kit (Beijing Shengqi Yangling Biotechnology Co. Ltd), heparin sodium (Nanjing Saurui Biotechnology Co. Ltd), and Hematoxylin-Eosin staining kit (Shenzhen Zike Biotechnology Co. Ltd).

All mice were inoculated with the Lewis cells to establish a mouse model of Lewis lung cancer. Then, the animals were assigned to blank control group, DTX group, DTX+Tα1 group, DTX + GM-CSF as well as DTX + Tα1 + GM-CSF groups. The tumor size of each group was measured 3 times a week, and body mass and tumor size of mice in each group were monitored. After the last dose of 24 h, the mice were weighed and sacrificed, and the tumor tissues were weighed. The percentage tumor inhibition was calculated as shown in Equation 1.
TI (%) = [(1 - MTMe) × 100]/MTMb ........ (1)

where TI is tumor inhibition, MTMe is mean tumor mass in each group, and MTMb is mean tumor mass in the blank control group.

The thymus and spleen were weighed, and the thymus index and spleen index were calculated as fractions of body mass. The concentrations of IL-6, TNF-α and IFN-α were assayed using ELISA. Levels of CD4+ and CD8+ T cells were determined flow cytometrically.

Statistical analysis

The results are expressed as mean ± standard deviation (SD). Two-group comparisons were done with t-test using SPSS 3.0 software. Values of $p<0.05$ were considered as indicative of statistical significance of differences.

RESULTS

Body mass, tumor mass and tumor inhibition

The mass of mice in DTX, DTX + Ta1, DTX+GM-CSF and DTX+Ta1+GM-CSF groups were markedly lower than corresponding blank control values ($p<0.05$). The body mass was higher in DTX + Ta1 + GM-CSF mice than in DTX mice, and body mass of mice in DTX + Ta1 + GM-CSF group was markedly higher than that of mice in DTX + Ta1 and DTX + GM-CSF groups ($p<0.05$). These results are shown in Table 1. Relative to blank control, mice mass was markedly decreased in DTX, DTX + Ta1, DTX + GM-CSF and DTX + Ta1 + GM-CSF groups ($p<0.05$).

However, mice weight in DTX + Ta1 + GM-CSF group was decreased, relative to DTX + Ta1, DTX + GM-CSF, and DTX groups ($p<0.05$). The % anti-tumor effects in the DTX group, DTX + Ta1 group, DTX + GM-CSF group and DTX + Ta1 + GM-CSF group were markedly elevated, relative to blank control ($p<0.05$). Tumor inhibition was markedly higher in DTX + Ta1 + GM-CSF mice than in DTX and DTX + Ta1 mice.

Thymus and spleen indices

The mass of thymus and the thymus index of DTX group, DTX + Ta1 group, DTX+GM-CSF group, DTX+ Ta1+GM-CSF group, as well as spleen mass and spleen index were significantly lower than the corresponding values in the blank control group ($p<0.05$). The thymus mass, thymus index, spleen mass and spleen index of mice in DTX + Ta1 group, the DTX + GM-CSF group and the DTX + Ta1 + GM-CSF group were markedly higher than those of DTX-treated mice ($p<0.05$). Moreover, thymus mass values of mice in DTX + Ta1 + GM-CSF group, thymus index, spleen mass and spleen index were markedly high, relative to mice in DTX + Ta1 and DTX + GM-CSF groups ($p<0.05$; Table 2).

Serum cytokine values

Levels of TNF-α, IL-6 and IFN-γ in DTX group, DTX + Ta1 mice, DTX + GM-CSF group and DTX + Ta1 + GM-CSF group were markedly reduced, relative to the blank control group, while levels of IL-6, TNF-α and IFN-γ of mice were markedly higher in DTX + Ta1 group, DTX + GM-CSF group and DTX + Ta1 + GM-CSF group those in DTX-treated mice ($p<0.05$).

Table 1: Mass of mouse and tumor inhibition rate

<table>
<thead>
<tr>
<th>Group</th>
<th>Mass of mouse (g)</th>
<th>Mass of tumor (g)</th>
<th>Inhibition (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank control</td>
<td>32.62 ± 2.02</td>
<td>1.80 ± 0.24</td>
<td>0</td>
</tr>
<tr>
<td>DTX</td>
<td>23.47 ± 2.13a</td>
<td>1.23 ± 0.12a</td>
<td>34.11a</td>
</tr>
<tr>
<td>DTX + Ta1</td>
<td>24.87 ± 1.53abc</td>
<td>1.03 ± 0.09abc</td>
<td>46.12abc</td>
</tr>
<tr>
<td>DTX + GM-CSF</td>
<td>25.90 ± 1.46abc</td>
<td>0.99 ± 0.07abc</td>
<td>48.01abc</td>
</tr>
<tr>
<td>DTX + Ta1 + GM-CSF</td>
<td>27.64 ± 1.53ab</td>
<td>0.71 ± 0.10ab</td>
<td>65.33ab</td>
</tr>
</tbody>
</table>

$aP<0.05$, vs blank control; $bP<0.05$, vs DTX mice, $cP<0.05$, vs DTX + Ta1 + GM-CSF group

Table 2: Thymus index and spleen index of mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Mass of thymus(mg)</th>
<th>Thymus index(mg/g)</th>
<th>Mass of spleen(mg)</th>
<th>Spleen index(mg/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank control</td>
<td>95.32 ± 16.13</td>
<td>3.04 ± 0.84</td>
<td>155.43 ± 11.17</td>
<td>4.89 ± 0.56</td>
</tr>
<tr>
<td>DTX</td>
<td>41.49 ± 11.04a</td>
<td>1.88 ± 0.80a</td>
<td>81.58 ± 12.53a</td>
<td>3.60 ± 0.74a</td>
</tr>
<tr>
<td>DTX + Ta1</td>
<td>48.60 ± 9.37abc</td>
<td>2.06 ± 0.79abc</td>
<td>98.86 ± 9.50abc</td>
<td>4.10 ± 0.83abc</td>
</tr>
<tr>
<td>DTX + GM-CSF</td>
<td>49.49 ± 9.74abc</td>
<td>2.02 ± 0.82abc</td>
<td>99.74 ± 10.36abc</td>
<td>3.98 ± 0.92abc</td>
</tr>
<tr>
<td>DTX + Ta1 + GM-CSF</td>
<td>59.45 ± 9.08ab</td>
<td>2.27 ± 1.00ab</td>
<td>118.57 ± 11.20ab</td>
<td>4.41 ± 0.94ab</td>
</tr>
</tbody>
</table>

$aP<0.05$, vs blank control; $bP<0.05$, vs DTX mice, $cP<0.05$, vs DTX + Ta1 + GM-CSF group
Lan et al.  

Table 3: Serum cytokine levels (pg/mL)

<table>
<thead>
<tr>
<th>Group</th>
<th>IL-6</th>
<th>TNF-α</th>
<th>IFN-γ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank control</td>
<td>443.43 ± 9.06</td>
<td>612.39 ± 7.00</td>
<td>73.27 ± 3.68</td>
</tr>
<tr>
<td>DTX</td>
<td>310.87 ± 7.96 a</td>
<td>356.24 ± 6.38 a</td>
<td>37.35 ± 3.90 a</td>
</tr>
<tr>
<td>DTX + Tα1</td>
<td>357.65 ± 7.04 abc</td>
<td>399.09 ± 7.45 abc</td>
<td>47.35 ± 3.14 abc</td>
</tr>
<tr>
<td>DTX + GM – CSF</td>
<td>356.34 ± 8.49 abc</td>
<td>412.36 ± 7.30 abc</td>
<td>52.95 ± 3.56 abc</td>
</tr>
<tr>
<td>DTX + Tα1 + GM – CSF</td>
<td>398.24 ± 8.74 abc</td>
<td>498.16 ± 6.43 abc</td>
<td>61.50 ± 3.39 abc</td>
</tr>
</tbody>
</table>

<sup>a</sup>P < 0.05, vs blank control; <sup>b</sup>p < 0.05, vs DTX group, <sup>c</sup>p < 0.05, compared with DTX + Tα1 + GM-CSF group

Table 4: T cell levels

<table>
<thead>
<tr>
<th>Group</th>
<th>CD4&lt;sup&gt;+&lt;/sup&gt;(10&lt;sup&gt;9&lt;/sup&gt;/L)</th>
<th>CD8&lt;sup&gt;+&lt;/sup&gt;(10&lt;sup&gt;9&lt;/sup&gt;/L)</th>
<th>CD4&lt;sup&gt;+&lt;/sup&gt;/CD8&lt;sup&gt;+&lt;/sup&gt; (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blank control</td>
<td>15.37 ± 0.53</td>
<td>8.38 ± 1.03</td>
<td>2.43 ± 1.00</td>
</tr>
<tr>
<td>DTX</td>
<td>9.89 ± 0.63&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.32 ± 0.82&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.95 ± 0.67&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>DTX+Tα1</td>
<td>10.34 ± 0.96&lt;sup&gt;abc&lt;/sup&gt;</td>
<td>5.24 ± 0.75&lt;sup&gt;abc&lt;/sup&gt;</td>
<td>2.10 ± 0.89&lt;sup&gt;abc&lt;/sup&gt;</td>
</tr>
<tr>
<td>DTX+GM-CSF</td>
<td>13.45 ± 0.59&lt;sup&gt;abc&lt;/sup&gt;</td>
<td>6.37 ± 0.92&lt;sup&gt;abc&lt;/sup&gt;</td>
<td>2.12 ± 1.03&lt;sup&gt;abc&lt;/sup&gt;</td>
</tr>
<tr>
<td>DTX+Tα1+GM-CSF</td>
<td>14.67 ± 0.80&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>7.30 ± 1.05&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>2.24 ± 0.95&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>P < 0.05, vs blank control; <sup>b</sup>p < 0.05, vs DTX mice, <sup>c</sup>p < 0.05, vs DTX + Tα1 + GM - CSF group

Mice in DTX + Tα1 + GM-CSF group had significantly higher concentrations of these cytokines than those in DTX + Tα1 group and DTX + GM - CSF group (p < 0.05).

T cell levels

Table 4 shows that the number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD4<sup>+</sup>/CD8<sup>+</sup> ratio of mice in DTX group, DTX+ Tα1 group, DTX+ GM-CSF group and DTX+ Tα1+ GM-CSF group were significantly lower than values in blank control mice (p < 0.05). Moreover, the CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts and CD4<sup>+</sup>/CD8<sup>+</sup> ratios of mice in DTX + Tα1 group, DTX + GM-CSF group and DTX + Tα1 + GM-CSF group were markedly higher than DTX-treated mice values (p < 0.05). The CD4<sup>+</sup> and CD8<sup>+</sup> T cells and CD4<sup>+</sup>/CD8<sup>+</sup> ratio of mice in DTX + Tα1 + GM-CSF group were markedly higher than those in DTX + Tα1 and DTX+ GM-CSF groups (p < 0.05).

DISCUSSION

Lung cancer constitutes a serious threat to human life. The incidence of the disease has gradually increased, while the survival of patients has decreased, with a value of 25% for stage IIB lung cancer [11]. Surgery is the most effective strategy for early-stage lung cancer. Peripheral small lung cancer is associated with a 5-year survival of 80%. Platinum-linked chemotherapy (the most representative of which is DTX) is popularly employed for treating individuals with advanced pulmonary carcinoma [12].

Docetaxel (DTX), a diterpenoid and a semi-synthetic analogue of paclitaxel, is vital for maintaining vascular stability and initiating cytotoxicity. It enhances apoptosis of tumor cells more effectively than paclitaxel [13]. Docetaxel has been widely used in clinical practice with satisfactory results. However, the toxicity and side effects such as bone marrow suppression, neutrophilia and allergy due to DTX seriously affect the health of patients, leading to decline in their immune function and reduced drug tolerance. It has been reported that DTX suppresses immune response in mice due to atrophy of lymphoid organs and severe impairment of immune function [14].

The GM-CSF is a hematopoietic factor that maintains innate immune homeostasis, and its production is regulated by various cytokines and antigens. It was originally present as a pro-inflammatory factor, and has been confirmed as an immunoregulatory factor in other studies [15]. The GM-CSF receptor reduces the body's tolerance and inhibits tumor growth. At present, GM-CSF has become a widely used immune stimulation adjuvant in clinical practice. Immune cells are regulated by Tα1, which also enhances immune response and produces relevant biological effects on target cells. Thus, Tα1 is beneficial for the reduction of oxidative damage caused by chemotherapy drugs [16].

The results obtained in this study showed that body mass, tumor mass, thymus mass, thymus index, spleen mass, spleen index, IL-6, TNF-α, IFN-γ, CD4<sup>+</sup>, CD8<sup>+</sup> T cell number and CD4<sup>+</sup>/CD8<sup>+</sup> ratio in DTX + Tα1 group, DTX + GM-CSF group, and DTX + Tα1 + GM-CSF group were markedly reduced, when compared with blank control values, and % tumor inhibition was markedly higher than values in blank control, DTX + Tα1 and DTX + GM-CSF groups. Moreover, body mass, thymus mass, thymus index, spleen mass, spleen index, IL-6,TNF-α, IFN-γ, CD4<sup>+</sup>, CD8<sup>+</sup> T cell number and CD4<sup>+</sup>/CD8<sup>+</sup> ratio in DTX + Tα1 + GM-CSF group were significantly higher than those in DTX, DTX + Tα1 and DTX + GM-CSF groups. In addition,
tumor mass values in DTX + Tα 1 and DTX+GM-CSF groups were markedly decreased, relative to those in DTX + Tα 1 and DTX + GM-CSF groups. These findings indicate that combined treatment with GM-CSF and Tα 1 effectively alleviates DTX-induced decreases in body mass and inhibits tumor growth in mice, while effectively alleviating DTX-induced thymic and splenic injuries. Moreover, the combination treatment can reverse the DTX-induced increases in levels of cytokines, suppress decreases in T cell number, and increase the population of T cells.

CONCLUSION
These results indicate that GM-CSF-Tα1-DEX combination treatment effectively enhances the resistance of mice and suppresses body mass reduction caused by chemotherapy. At the same time, it can effectively reduce the levels of cytokines, and enhance T lymphocyte-mediated cellular immunity. Low immunity may be a predisposing factor for tumors, and the occurrence of tumor may also lead to the suppression of anti-tumor immunity. Thus, the enhancement of immune function of tumor patients is an important clinical treatment strategy.

DECLARATIONS

Acknowledgement
This study was supported by Natural Science Foundation of Guangxi Zhuang Autonomous Region (no. 2017GXNSFAA198062).

Conflict of interest
No conflict of interest is associated with this work.

Contribution of authors
We declare that this work was done by the author(s) named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. All authors read and approved the manuscript for publication. Haiyan Lan conceived and designed the study, Haiyan Lan, Yanrong Hao, Yanru Lv, Guangyu Li, Yuncong Mo, Cheng Zheng, while Yuanfa Li collected and analysed the data. Haiyan Lan wrote the manuscript.

Open Access
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES
11. Lambros L, Guilbour B, Uguen A. ROS1-rearranged Non-Small Cell Lung Cancers with Concomitant


